Defence Therapeutics Inc.
DTC
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -82.54% | 114.54% | 200.80% | 252.30% | 307.32% |
| Depreciation & Amortization | 405.84% | 256.85% | 554.90% | 232.29% | 63.83% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -74.59% | 58.66% | 93.68% | 86.50% | 73.79% |
| Operating Income | 74.59% | -58.66% | -93.68% | -86.50% | -73.79% |
| Income Before Tax | 70.43% | -56.21% | -89.63% | -84.73% | -73.91% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 70.20% | -58.48% | -92.56% | -83.30% | -72.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 70.20% | -58.48% | -92.56% | -83.30% | -72.56% |
| EBIT | 74.59% | -58.66% | -93.68% | -86.50% | -73.79% |
| EBITDA | 75.16% | -58.15% | -161.31% | -326.60% | -611.39% |
| EPS Basic | 71.48% | -46.24% | -69.73% | -55.67% | -46.64% |
| Normalized Basic EPS | 71.72% | -44.18% | -67.24% | -56.66% | -47.62% |
| EPS Diluted | 71.48% | -46.24% | -69.73% | -55.67% | -46.64% |
| Normalized Diluted EPS | 71.72% | -44.18% | -67.24% | -56.66% | -47.62% |
| Average Basic Shares Outstanding | 6.96% | 9.85% | 13.67% | 17.21% | 15.41% |
| Average Diluted Shares Outstanding | 6.96% | 9.85% | 13.67% | 17.21% | 15.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |